Last October, Johnson and Johnson was fined $8 billion in punitive damages by the Philadelphia Civil Procedure Court in Pennsylvania for causing a male to develop abnormally in his chest. At the time, it was considered the largest amount of compensation in 13,000 lawsuits involving the product. But on January 17th the Philadelphia court decided to reduce that amount to $6.8 million in damages.
According to public court records, the judge did not specify the amount of punitive damages, Reuters reported. But lawyers for the plaintiff, Nicholas Murray, said, “This is a wrong judgment, and this kind of punishment is meaningless to the business”, “I believe the final compensation will still be $8 billion.”
According to Murray, a 26-year-old plaintiff, he was diagnosed with autism spectrum disorder in 2003 and took the prescription drug Risperdal, a prescription drug prescribed by a doctor, after which he developed abnormal breast development. He noted that Johnson and Johnson had never made a risk warning about allegedly concealing the relationship between lipoxasideand and male breast development.
In 2015, the case was initially awarded by a jury, and Johnson and Johnson awarded the man $1.75 million, which was eventually set at $680,000 in a 2018 appeal judgement, and Johnson and Johnson paid. But both sides said they would appeal again.
On October 8, 2019, a Philadelphia court ordered Johnson and Johnson to pay $8 billion in punitive damages to the man. “This is an excessive and baseless ruling,” Johnson and Johnson said in a statement on the same day.